Eli Lilly and Co (NYSE: LLY) has reported earnings for its third fiscal quarter (ending September 30) of $1.07 versus a loss $-0.06 for the same period a year ago — a decline of -1883%. For the latest four quarters through September 30, E.P.S. were $9.26 compared to $5.54 a year ago — an increase of 67%.
Recent Price Action
Eli Lilly and Co (NYSE: LLY) stock closed at $846.83 on 10/30/24 after a large decline of -6.3%. Moreover, trading volume in this decline was exceptionally high at 656% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -6.9% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, LLY is expected to continue to be a major Value Builder.
Eli Lilly has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Eli Lilly has a neutral Appreciation Score of 49 but a very high Power Rating of 86, with the Positive Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment